Rare condition

Chronic intestinal failure

ORPHA:294422 ↗Clinical syndrome

10

studies recruiting now

as of 7 Sept 2026

70

studies registered in total

as of 7 Sept 2026

3

countries with a recruiting site

as of 7 Sept 2026

2 Jun 2026

most recent study posted

among recruiting studies

Recruiting trials

Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.

See all 10 recruiting studies

Where recruiting studies are running

Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.

Keep watching

Get an email when a new Chronic intestinal failure study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

About Chronic intestinal failure

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.

Treatments being studied

8 approved treatments and 39 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Epoetin Beta (Neorecormon)Approved: Epoetin Theta (Biopoin)Approved: BixalomerApproved: Epoetin Zeta (Retacrit)Approved: Methoxy Polyethylene Glycol-Epoetin Beta (Mircera)Approved: Epoetin Alfa (Abseamed)Approved: Darbepoetin Alfa (Aranesp)Approved: Lanthanum Carbonate (Fosrenol)
Phase 3Angiotensin
Phase 3Heparin Sodium (Heparin lock flush)
Phase 3Cyclosporine (Capimune)
Phase 3Everolimus (Afinitor)
Phase 3Flurandrenolide (Cordran)
Phase 3Irbesartan (Aprovel)
Phase 3Pentoxifylline (Neotren mr)
Phase 3Sevelamer

+ 31 more in development

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).